| 6.2 -0.11 (-1.74%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.31 | 1-year : | 9.13 |
| Resists | First : | 7.11 | Second : | 7.82 |
| Pivot price | 6.42 |
|||
| Supports | First : | 5.97 | Second : | 4.97 |
| MAs | MA(5) : | 6.28  |
MA(20) : | 6.57 |
| MA(100) : | 7.29 |
MA(250) : | 6.24 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 21.8 |
D(3) : | 22.7 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 9.61 | Low : | 3.52 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ DTIL ] has closed above bottom band by 28.2%. Bollinger Bands are 46.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.41 - 6.44 | 6.44 - 6.47 |
| Low: | 6.03 - 6.07 | 6.07 - 6.09 |
| Close: | 6.15 - 6.2 | 6.2 - 6.25 |
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Tue, 06 Oct 2026
Director bought 1,135 shares of Precision BioSciences stock - AD HOC NEWS
Mon, 05 Oct 2026
Price to book forward of Precision BioSciences, Inc. – NASDAQ:DTIL - TradingView
Sun, 04 Oct 2026
Precision BioSciences outlines two clinical programs and 5 analysts cover DTIL stock - AD HOC NEWS
Wed, 30 Sep 2026
At $6 per share, a director buys 1,000 Precision Biosciences (DTIL) shares - Stock Titan
Sun, 27 Sep 2026
How Precision Biosciences Inc. (DTIL) Affects Rotational Strategy Timing - Stock Traders Daily
Mon, 21 Sep 2026
Precision BioSciences (Nasdaq:DTIL) - Stock Analysis - Simply Wall Street
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 28 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 8 (%) |
| Held by Institutions | 68.6 (%) |
| Shares Short | 2,400 (K) |
| Shares Short P.Month | 2,380 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.71 |
| Profit Margin | -117.1 % |
| Operating Margin | -80.8 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -135.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 1.63 |
| Sales Per Share | 1.63 |
| EBITDA (p.s.) | -1.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -52 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -4.7 |
| PEG Ratio | 0 |
| Price to Book value | 3.62 |
| Price to Sales | 3.79 |
| Price to Cash Flow | -3.3 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|